ReviewAllergy2025
Fungal-Driven Airways Dis-Immunity From Asthma to Allergic Bronchopulmonary Aspergillosis: Dissecting Similarities and Differences. An EAACI Task Force Report.
Review in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biologic switching in allergic bronchopulmonary aspergillosis: a scoping review of published clinical experience.Journal of thoracic disease · 2026Review
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe asthma and allergic bronchopulmonary aspergillosis (ABPA) do not rarely coexist and share several similarities in terms of pathobiological background, together with overlapping clinical manifestations, misleading the correct diagnosis. Within that scenario, severe asthma with fungal sensitization (SAFS) further complicates the correct pheno-endotyping, which still needs to be recognized in the light of the greater burden and higher risk of irreversible damage related to ABPA and SAFS when compared to asthma alone. The identification of pathobiological drivers underlying different conditions remains challenging; in fact, available biomarkers, although accurate when related to each specific condition, do not always fully support a clear-cut differential diagnosis. The opportunity for innovative targeted treatments, although needing further evidence, should further stimulate a precise endo-phenotyping of severe asthma patients presenting some hallmarks of fungal-related dis-immunity to provide them the best standard of care for preventing disease evolution and achieving complete remission. This review provides a comparative outline of the recent advances in terms of pathophysiology, clinical manifestations, biomarkers, and management of asthma and ABPA, including a focus on SAFS, with the aim of updating the practical approach to those conditions and supporting their correct recognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.